![]() |
9TH EUROPEAN AIDS CONFERENCE (EACS) 1st EACS RESISTANCE & PHARMACOLOGY WORKSHOP October 25 - 29, 2003 Warsaw, Poland |
| 9.2 Disturbances in Lipid and Glucose Metabolism F8/3 - FAVOURABLE INCREASES IN HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) CONCENTRATIONS IN CHRONIC HIV-INFECTED THERAPY NAÏVE SUBJECTS RECEIVING 908/R QD IN THE SOLO STUDY |
| (1) Hospital of Infectious Disease, Warsaw, Poland,2 University Clinic Frankfurt/M, Germany,3 University Health Network - Toronto General Hospital, Canada,4 Treasure Coast Infectious Disease Consultants, Florida, USA,5 GlaxoSmithKline R&D RTP, USA,6 GlaxoSmithKline R&D, Greenford, UK |
Background: Chronic HIV infection is associated with decreases in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and HDL-C. In HIV negative subjects, low HDL-C (<40mg/dL) and high TC/HDL-C ratios are associated with an increased risk for cardiovascular disease. Currently available protease inhibitors (PI) have often been associated with increases in TC and LDL-C but little change in HDL-C.
Method: In SOLO, a 48-week randomised study, 322 subjects received 908/r QD (NFV: 327). Serum samples were collected in fasting state. Dyslipidemia was defined according to the US National Cholesterol Education Programme cut-offs.
Results: At baseline (BL), the mean HDL-C level was 38mg/dL (NFV: 37mg/dL). After starting 908/r QD, mean HDL-C increased over 48 weeks to 46mg/dL (+ 29%; NFV: +27%). TC increased by 38% (NFV: +37%), but with minimal changes in TC/HDL-C ratio (mean +0.39; NFV: +0.34) observed.
| 908/r QD (N=232) | 908/r QD | NFV BID (N=245) | NFV BID | |
| Observed Analysis | BL | Wk 48 | BL | Wk 48 |
| % with HDL-C <40mg/dL | 60 | 25 | 68 | 31 |
| % with HDL-C >40mg/dL and < 60mg/dL | 36 | 61 | 28 | 51 |
| % with HDL-C >60mg/dL | 4 | 15 | 4 | 18 |
| % with TC/HDL-C ratio >6.5 | 15 | 18 | 9 | 14 |
Conclusion: In this chronically HIV infected ART-naïve population with low BL HDL-C, substantial increases in HDL-C combined with minimal changes in the TC/HDL-C ratio were observed following treatment with 908/r QD and NFV for 48-weeks. Similar observations were previously reported with NNRTIs.
Presenting Author: Dr. Andrzej Horban, Hospital of Infectious Disease - AIDS Diagnosis and Therapy Center, 37, Wolska Str., PL - 01-, Warsaw, Poland, Phone: ++48-22-6320611
031025
41